Customer Services - 01371 851802
Your basket is empty
Select Delivery Region:
Four Seasons 2

Welcome to the Journal of Dementia Care

Become a member subscriber

Join a community of all professional staff working with people living with dementia

Sign up today

Already a member subscriber?

Hero Homepage

Member subscriber benefits

Member subscriber benefits
  • New: 15% discount on events and books

    Take advantage of the attractive 15% off the price of our books and conferences at any time of the day or night!

  • New: Read JDC online

    Read the current issue of JDC online and print it if you want

  • Receive printed copies of JDC by mail

    Enjoy the only national dementia publication for everyone working with people living with dementia

  • New: Receive the JDC weekly e-newsletter

    Receive a weekly round-up of dementia news carefully edited by JDC editor Mark Ivory

  • New: Keep up to date with industry news

    You can take advantage of our rolling 24-hour, dementia-focused newsfeed on this website.

Become a member subscriber

Sample Feature View Current Issue Contents Page

  • JDC Asks...

    JDC Asks...

    A rating of ‘inadequate’ from CQC can mean the care home goes out of business, while an ‘outstanding’ one can do wonders for business and morale. But do CQC ratings really reflect the standards of care delivered?

    Read More


News Update

  • “Broader understanding needed” as Alzheimer’s drug fails

    “Broader understanding needed” as Alzheimer’s drug fails

    20.02.17 Hopes of a drug treatment for Alzheimer’s disease have been dealt another blow by the failure of verubecestat during experimental trials. Pharmaceutical company Merck called a halt to the trial with people with mild to moderate Alzheimer’s, with “virtually no chance of finding a positive clinical effect.” Alzheimer’s Research UK policy director Dr Matthew Norton said that a broader understanding was needed of the neurological effects of dementia. “We need to understand the targets in the brain that we can hit with new treatments,” he said. “To use a football analogy, we’re just taking single long shots at the goal but we need to be starting and building up our attack from the back of the pitch.” Merck is to carry on evaluating verubecestat in people with prodromal Alzheimer’s disease on the basis that it may inhibit changes that occur in the brain prior to onset. Norton added: “Two or three drugs are coming in the next few years that we do have high hopes for.”

  • Historic venue and dates announced for UKDC and National Dementia Care Awards

    Historic venue and dates announced for UKDC and National Dementia Care Awards

    20.02.17 JDC is delighted to announce that this year’s 12th UK Dementia Congress will be held at the historic Doncaster Racecourse on 7 – 9 November. It will also be the venue for the 8th National Dementia Care Awards which will follow UKDC on the final day of the Congress. Proposals for presentations and posters at UKDC are invited on any aspect of support, care and treatment for people with dementia and their families, in any setting. Click HERE for further information.

JDC on Twitter

JDC on Facebook